Psyched: Cybin's Center Stage In Novel Psychedelics, Musk & Ramaswamy, Britney's Memoir And More
Portfolio Pulse from Lara Goldstein
Psychedelics companies Cybin Inc. and Small Pharma Inc. have completed their acquisition agreement, making Small Pharma a wholly-owned subsidiary of Cybin. The combined company has received two patent grants from the USPTO and one from the European Patent Office. The AdvisorShares Psychedelics ETF has been showing a descending trend in its opening and closing prices. Other psychedelics stocks such as GH Research, COMPASS Pathways, Mind Medicine, Enveric Biosciences, Bright Minds Biosciences, Silo Pharma, Atai Life Sciences, Incannex Healthcare, FSD Pharma, and Cybin Inc. have also seen changes in their closing prices.
October 30, 2023 | 2:48 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The AdvisorShares Psychedelics ETF has been showing a descending trend in its opening and closing prices.
The descending trend in the ETF's prices could indicate a bearish market sentiment, potentially driving the stock price down.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Tesla CEO Elon Musk has been mentioned in the context of his support for psychedelic drugs and their benefits.
While Elon Musk's views on psychedelic drugs could influence public opinion, it's unlikely to have a direct impact on Tesla's stock price.
CONFIDENCE 80
IMPORTANCE 30
RELEVANCE 20
POSITIVE IMPACT
Cybin Inc. has completed its acquisition of Small Pharma and received new patents, potentially strengthening its market position.
The completion of the acquisition could strengthen Cybin's market position and the new patents could provide a competitive edge, potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100